Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

US FDA grants fast track status to Gyroscope’s GT005 to treat dry age-related macular degeneration

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the US FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is intended to slow the […]

The post US FDA grants fast track status to Gyroscope's GT005 to treat dry age-related macular degeneration first appeared on World Pharma Today.



This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here

Share the post

US FDA grants fast track status to Gyroscope’s GT005 to treat dry age-related macular degeneration

×

Subscribe to Leading Pharmaceutical Industry Online Platform

Get updates delivered right to your inbox!

Thank you for your subscription

×